研究单位：[1]Southeast University, China[2]Beijing Tiantan Hospital, Capital Medical University Beijing, Beijing, China, 100000[3]The First Affiliated Hospital of Chongqing Medical University Chongqing, Chongqing, China, 404100[4]Qingyuan People's Hospital Qingyuan, Guangdong, China, 511500[5]Affiliated Hospital of Guizhou Medical University Guiyang, Guizhou, China, 550000[6]Affiliated Hospital of Zunyi Medical University Zunyi, Guizhou, China, 563000[7]The Fourth Hospital of Hebei Medical University Shijiazhuang, Hebei, China, 050000河北医科大学第四医院[8]First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan, China, 450000[9]Henan Provincial People's Hospital Zhengzhou, Henan, China, 450000[10]Enshi Tujia and Miao Autonomous Prefecture Central Hospital Enshi, Hubei, China, 445000[11]Yichang Central People's Hospital Yichang, Hubei, China, 443000[12]The Third Xiangya Hospital of Central South University Changsha, Hunan, China, 410000[13]Xiangya Hospital of Central South University Changsha, Hunan, China, 410000[14]Nanjing Zhong-Da Hospital, Southeast University Nanjing, Jiangsu, China, 210009[15]Northern Jiangsu People's Hospital Yangzhou, Jiangsu, China, 225000[16]Zhejiang Provincial People's Hospital Hangzhou, Zhejiang, China, 310000[17]The First Affiliated Hospital of Wenzhou Medical University Wenzhou, Zhejiang, China, 325000[18]Anhui Provincial Hospital Hefei, Anhui, China, 230000
Remifentanil has been approved by the FDA for continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting. However, National Medical Products Administration(NMPA) did not approve this indication. Therefore, the purpose of this study is to confirm the efficacy and safety of remifentanil in the analgesic therapy of critical ill patients in China.
